Dynamics of immunoinflammatory markers level on the background of quercetin therapy in patients with ischemic heart disease associated with hypothyroidism
DOI:
https://doi.org/10.15587/2313-8416.2016.59038Keywords:
immunonflammatory markers, ischemic heart disease, hypothyroidism, quercetinAbstract
The hypothyroidism in patients with ischemic heart disease favors its progression. The aim of research was to study the dynamics of immunoinflammatory markers level in patients with ischemic heart disease associated with hypothyroidism on the background of quercetin therapy.
Methods of research. 23 patients with ischemic heart disease: the stable exertion angina of I-III functional class with concomitant hypothyroidism took part in research. 13 patients underwent the standard basic therapy of ischemic heart disease and hypothyroidism; 10 patients received quercetin as an additional preparation to the main therapy. Using ummunosorbent method there were detected the level of alpha-tumor necrosis factor, C-reactive protein, endotelin-1, tissue activator inhibitor plasminogen-1, neopterin; using immunochemiluminiscent method there was detected the levels of thyrotropic hormone and Т4 free one.
Results. Under the influence of basic therapy including quercetin there was noticed the reliable decrease of endotelin-1 and alpha-tumor necrosis factor, was detected the tendentious decrease of tissue activator inhibitor plasminogen-1, C-reactive protein and neopterin in 3 month of treatment.
Conclusions. Basic therapy with quercetin as an additional preparation has a normalizing influence on the systemic inflammatory process and endothelial dysfunction and that grounds the expediency of the use of this complex pharmacotherapy in patients with ischemic heart disease associated with hypothyroidism
References
Mitchenko, O., Lohvynenko, A., Romanov, V. (2010). Optymizatsiya likuvannya dyslipidemiy ta porushen' vuhlevodnoho obminiv u khvorykh z metabolichnym syndromom ta dysfunktsiyeyu shchytopodibnoyi zalozy [Optimization of treatment of dyslipidemia and disorders of carbohydrate metabolism in patients with metabolic syndrome and thyroid dysfunction]. Ukrainian Journal of Cardiology, 1, 73–80.
Tseng, F.-Y., Lin, W.-Y., Lin, C.-C., Lee, L.-T., Li, T.-C., Sung, P.-K., Huang, K.-C. (2012). Subclinical Hypothyroidism Is Associated With Increased Risk for All-Cause and Cardiovascular Mortality in Adults. Journal of the American College of Cardiology, 60 (8), 730–737. doi: 10.1016/j.jacc.2012.03.047
D’Alessandris, C., Lauro, R., Presta, I., Sesti, G. (2007). C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. Diabetologia, 50 (4), 840–849. doi: 10.1007/s00125-006-0522-y
Dal Lin, C., Tona, F., Osto, E. (2015). Coronary Microvascular Function and Beyond: The Crosstalk between Hormones, Cytokines, and Neurotransmitters. International Journal of Endocrinology, 2015, 1–17. doi: 10.1155/2015/312848
Kostoglou-Athanassiou, I., Ntalles, K. (2010). Hypothyroidism – new aspects of an old disease. Hippokratia, 14 (2), 82–87.
Ayers, S., Webb, P. (2014). Thyroid hormone analogues: their role in treatment of hyperlipidemia. Journal of Endocrinology, Diabetes & Obesity, 2 (3), 1042. Available at: http://www.jscimedcentral.com/Endocrinology/endocrinology-spid-role-thyroid-hormone-metabolic-homeostasis-1042.pdf
Kravchun, P., Lapshina, L., Zolotaykina, V. (2012). Dinamika urovney leykotriena S4, faktorov nespetsificheskogo vospaleniya, markerov oksidativnogo stressa, kardiogemodinamiki pri vklyuchenii vodorastvorimoy formyi kvertsetina v terapiyu ostroy serdechnoy nedostatochnosti [Dynamics of C4 leukotriene, factors of nonspecific inflammation, oxidative stress markers, cardiac hemodynamics when the water-soluble form of quercetin in the treatment of acute heart failure]. Scientific statements Belgorod State University. A series of "Medicine. Pharmacy", 4, 100–110.
Netjazhenko, V. Z., Mal'chevskaja, T. I., Mishanich, G. I. et al. (2010). Vybor metabolicheskoj terapii pri lechenii bol'nyh s ishemicheskoj bolezn'ju serdca. Novosti mediciny i farmacii, 7 (320), 8.
Schor, J. (2010). The influence of quercetin on exercise performance and muscle mitochondria. Natural Medicine Journal, 2 (5). Available at: http://www.naturalmedicinejournal.com/journal/2010-05/influence-quercetin-exercise-performance-and-muscle-mitochondria
Zaafan, M. A., Zaki, H. F., El-Brairy, A. I., Kenawy, S. A. (2013). Protective effects of atorvastatin and quercetin on isoprenaline-induced myocardial infarction in rats. Bulletin of Faculty of Pharmacy, Cairo University, 51 (1), 35–41. doi: 10.1016/j.bfopcu.2013.03.001
Kumar, S., Pandey, A. K. (2013). Chemistry and Biological Activities of Flavonoids: An Overview. The Scientific World Journal, 2013, 1–16. doi: 10.1155/2013/162750
Jeong, S.-M., Kang, M.-J., Choi, H.-N., Kim, J.-H., Kim, J.-I. (2012). Quercetin ameliorates hyperglycemia and dyslipidemia and improves antioxidant status in type 2 diabetic db/db mice. Nutrition Research and Practice, 6 (3), 201. doi: 10.4162/nrp.2012.6.3.201
Perez-Vizcaino, F., Duarte, J. (2010). Flavonols and cardiovascular disease. Molecular Aspects of Medicine, 31 (6), 478–494. doi: 10.1016/j.mam.2010.09.002
Gunduz, M., Gunduz, E., Kircelli, F., Okur, N., Ozkaya, M. (2012). Role of Surrogate Markers of Atherosclerosis in Clinical and Subclinical Thyroidism. International Journal of Endocrinology, 2012, 1–6. doi: 10.1155/2012/109797
Lee, J. H., Shin, Y.-J., Oh, J.-H., Lee, Y.-J. (2012). Pharmacokinetic interactions of clopidogrel with quercetin, telmisartan, and cyclosporine A in rats and dogs. Archives of Pharmacal Research, 35 (10), 1831–1837. doi: 10.1007/s12272-012-1017-7
Pavlyukovych, N., Trefanenko, I., Pavlyukovych, O. (2013). Bilkovyy ta lipidnyy spektr krovi pry poyednanomu perebihu ishemichnoyi khvoroby sertsya ta khronichnoho nekal'kul'oznoho kholetsystytu: terapevtychni mozhlyvosti kvertsetynu [Protein and lipid spectrum of the blood flow combined with coronary heart disease and chronic non-calculous cholecystitis: therapeutic possibilities quercetin]. Medical Journal of Bukovina, 17 (3), 172–176.
Gergerlioglu, H., Demir, E., Alp, M., Oz, M. (2015). Effects of quercetin in IL-6 and TNF-α levels in diabetic rats. The FASEB Journal, 29 (1).
Mahmoud, M. F., Hassan, N. A., El Bassossy, H. M., Fahmy, A. (2013). Quercetin Protects against Diabetes-Induced Exaggerated Vasoconstriction in Rats: Effect on Low Grade Inflammation. PLoS ONE, 8 (5), e63784. doi: 10.1371/journal.pone.0063784
Wang, L., Chen, J., Wang, B., Wu, D., Li, H., Lu, H. et. al (2014). Protective effect of quercetin on lipopolysaccharide-induced acute lung injury in mice by inhibiting inflammatory cell influx. Experimental Biology and Medicine, 239 (12), 1653–1662. doi: 10.1177/1535370214537743
Downloads
Published
Issue
Section
License
Copyright (c) 2016 Тетяна Вікторівна Олійник, Наталія Сергіївна Михайловська
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
